Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;30(7):414-426.
doi: 10.1089/cap.2020.0004. Epub 2020 Jul 9.

Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

Affiliations

Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

Deborah A Pearson et al. J Child Adolesc Psychopharmacol. 2020 Sep.

Abstract

Objective: To examine the effectiveness of four doses of psychostimulant medication, combining extended-release methylphenidate (ER-MPH) in the morning with immediate-release MPH (IR-MPH) in the afternoon, on cognitive task performance. Method: The sample comprised 24 children (19 boys and 5 girls) who met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-R and the Autism Diagnostic Observation Schedule, and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient = 85; SD = 16.8). Effects of placebo and three dose levels of ER-MPH (containing 0.21, 0.35, and 0.48 mg/kg equivalent of IR-MPH) on cognitive task performance were compared using a within-subject, crossover, placebo-controlled design. Each of the four MPH dosing regimens (placebo, low-dose MPH, medium-dose MPH, and high-dose MPH) was administered for 1 week; the dosing order was counterbalanced across children. Results: MPH treatment was associated with significant performance gains on cognitive tasks tapping sustained attention, selective attention, and impulsivity/inhibition. Dose/response was generally linear in the dose range studied, with no evidence of deterioration in performance at higher MPH doses in the dose range studied. Conclusion: The results of this study suggest that MPH formulations are associated with significant improvements on cognitive task performance in children with ASD and ADHD.

Keywords: ADHD; ASD; cognitive tasks; stimulants.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Study recruitment and retention.
FIG. 2.
FIG. 2.
Performance on the continuous performance task as a function of methylphenidate dose.

References

    1. Aman MG: Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil 8:347–365, 1996
    1. Aman MG, Kern RA, McGhee DE, Arnold LE: Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: Laboratory effects. J Autism Dev Disord 23:491–506, 1993 - PubMed
    1. Aman MG, Lam KSL, Van Bourgondien ME: Medication patterns in patients with autism: Temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15:116–126, 2005 - PubMed
    1. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN: Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30:246–256, 1991a - PubMed
    1. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN: Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30:816–824, 1991b - PubMed

Publication types

MeSH terms

Substances